Korsana Biosciences, Inc. (KRSA)

Market Cap	1.41B +17,977.6%
Revenue (ttm)	n/a
Net Income	-49.08M
EPS	-13.37
Shares Out	45.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,195
Open	31.43
Previous Close	32.00
Day's Range	30.75 - 32.03
52-Week Range	7.19 - 59.36
Beta	1.75
Analysts	Strong Buy
Price Target	35.33 (+13.97%)
Est. Earnings	Nov 11, 2026

About KRSA

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2024
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: KRSA
• Website: https://korsana.com

Analyst Summary

According to 3 analysts, the average rating for KRSA stock is "Strong Buy." The 12-month stock price target is $35.33, which is an increase of 13.97% from the latest price.

Price Target

$35.33

(13.97% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 1, 2026

Data Sources Report a data error